Live Breaking News & Updates on Endometriosis Special Interest Group

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Myovant Sciences Announces Corporate Updates and Financial Results for Third Quarter of Fiscal .
Myovant Sciences, Inc.February 11, 2021 GMT
ORGOVYX™ (relugolix) approved by the 
U.S. Food and Drug Administration  (FDA) in December 2020 as the first and only oral GnRH receptor antagonist for adult patients with advanced prostate cancer; ORGOVYX launched in the U.S. in early January 2021
Announced collaboration with Pfizer in December 2020 to jointly develop and commercialize relugolix in oncology and relugolix combination tablet in women’s health in the U.S. and Canada ....

New York , United States , City Of , United Kingdom , Sumitomo Dainippon Pharma , David Marek , Albert Liao , Bryan Crowe , Endometriosis Special Interest Group , Dainippon Pharmaceutical Co Ltd , European Union , Virtual Congress , American Society For Reproductive Medicine , Canada The Co , European Commission , Drug Administration , Myovant Sciences , Gedeon Richter , Exchange Commission , Myovant Sciences Ltd , Corporate Communications , Myovant Sciences Inc , European Medicines Agency , Scientific Congress Prize Paper Session , Sumitomo Dainippon Pharma Co Ltd , Sumitomo Pharmaceuticals Co Ltd ,